Member Info for highland

Basically....he is a winner with what appears to be the Midas Touch

Yes, Ronjon Nag is a highly successful businessman, entrepreneur, and investor. His achievements in the fields of artificial intelligence (AI), mobile technology, and venture capital highlight his success. Here’s why:

1. Entrepreneurial Success

Co-founded Lexicus (Acquired by Motorola)

Developed AI-driven handwriting recognition technology.

Sold to Motorola in 1993.

Founded Cellmania (Acquired by BlackBerry)

A pioneering mobile app store platform before Apple and Google dominated the space.

Sold to BlackBerry in 2010.

Advised Companies Acquired by Apple

Provided expertise in AI and mobile technology.

2. AI and Investment Ventures

Founder of R42 Group

A venture capital firm investing in AI, longevity, and biotechnology startups.

Focuses on cutting-edge innovations, particularly in life sciences and aging research.

Board Member & Investor in Several AI and Biotech Companies

Includes Healx.ai (AI-driven drug discovery) and Agemica.ai (AI for anti-aging research).

3. Academic & Industry Recognition

Stanford University Fellow & Instructor

Teaches AI-related courses and mentors entrepreneurs.

Recognized Inventor

Holds over 40 patents in AI, mobile technology, and communications.

4. Net Worth & Financial Success

While his exact net worth is undisclosed, his track record of multi-million-dollar acquisitions and investments in high-growth startups indicates significant financial success.

Conclusion

Ronjon Nag is undoubtedly a successful businessman, having built and sold multiple tech companies, invested in promising AI ventures, and contributed to academic and industry innovation. His ability to anticipate technological trends and build businesses around them has made him a respected figure in AI and mobile tech.

You said:

how successful financially

ChatGPT said:

​Dr. Ronjon Nag is a distinguished inventor, entrepreneur, and educator with a career spanning over four decades in artificial intelligence (AI) and mobile technology. He co-founded companies such as Lexicus and Cellmania, which were acquired by Motorola in 1993 and BlackBerry in 2010, respectively. Additionally, he has advised companies acquired by Apple. ​

Beyond these ventures, Dr. Nag is the founder of the R42 Group, a venture capital firm investing in AI and longevity companies. He also holds an adjunct professorship in Genetics at Stanford School of Medicine. ​

brventurefund.com

+3

BusinessCloud

+3

Clinical Trials

+3

While these accomplishments indicate significant financial success, specific details about Dr. Nag's personal net worth are not publicly disclosed. Therefore, any estimations of his personal wealth would be speculative.

I agree.

Ronjon has spent years building up a solid reputation, is highly regarded in his field and I cannot for one second believe he would put all of that on the line to deal with amateurs. This is looking like a very sound investment to me, in my opinion.

Grabbed myself another cheeky 300, 000 shares

To estimate the potential market cap of Capai, a company led by Ronjon Nag within the AI space, we would need to consider several factors, such as Ronjon Nag's history, the company's business model, growth potential, and industry trends.

Key considerations:

Ronjon Nag’s Experience and Track Record: Ronjon Nag has significant experience in the tech industry, particularly in the areas of AI and mobile technology. He has been involved in founding and leading successful companies like Slyce, a mobile visual search company, and has contributed to AI and mobile innovations. His background suggests that he understands how to scale a tech company, navigate complex markets, and attract investment.

AI Industry Growth: The AI industry is experiencing rapid growth, with global AI market size expected to reach over $1.5 trillion by 2030. AI companies that capture significant market share or create breakthrough products can achieve substantial valuations. The AI market includes sectors like healthcare, automotive, enterprise software, robotics, and more. Moderate success in these areas could see a company like Capai grow significantly.

Moderate Success Trajectory: If Capai were moderately successful, it might capture a portion of the market through AI-driven products or services that meet evolving demand. A moderately successful AI company could see valuations in the range of:

$1 billion to $10 billion for companies with a strong but niche product.

$10 billion to $50 billion for companies that disrupt major industries or form strategic partnerships.

Companies with significant AI technology and moderate success in scaling could even exceed these ranges over time, particularly if they achieve strong customer growth, develop intellectual property, or expand internationally.

Examples of Similar Companies:

Nvidia, a company that has become a major player in AI hardware and software, has seen its market cap soar over $1 trillion. While Capai may not reach that scale in the short term, moderate success could still lead to a market cap in the $10 billion to $50 billion range, depending on product adoption and industry penetration.

UiPath, a company focused on robotic process automation (RPA), reached a market cap of over $35 billion during its IPO, demonstrating the potential for AI-related companies to achieve significant market valuations even with relatively niche applications.

Conclusion:

If Capai were to be moderately successful in the AI space, based on Ronjon Nag's history and the rapid growth of AI markets, a reasonable estimate for its market cap could range between $1 billion to $10 billion, with the potential for growth to higher levels if it achieves strong adoption and scalability in key AI applications. However, precise projections would depend on the specifics of Capai's product, market penetration, and overall execution.

More the merrier if they are all like that one....

I wonder if there is any reason why Tim did the Sunday Roast podcast rather than his normal Proactive interview...would Proactive not reach the ears of many more people?

Finally think the potential of this is starting to dawn ....this could be huge.

A Proactive Investor interview with Tim later....he did say previously he was going to be a regular visitor.

Avocet,

notice the word "could"...nothing is certain, but I will take my chances

That is a very bullish statement to be honest....

Matters not how much it rises today, in the long run this could be absolutely huge!

Steady flow of news on here over the last few days...seem to be making good use of their downtime during suspension.

Is it not 17,000,000 GBP rather than $?

Price is all over the place....

The acquisition price for a company with a groundbreaking diagnostic tool and treatment for a wide array of autoimmune diseases could vary significantly, depending on multiple factors. Generally, large pharmaceutical companies are willing to pay a premium for unique and highly valuable intellectual property like the one you've described, particularly if the technology has proven efficacy and a significant market opportunity.

Here are some key considerations that could affect the acquisition price:

Proven Clinical Efficacy: If the diagnostic tool and treatment have undergone rigorous clinical trials with strong evidence of their effectiveness, that would substantially increase the value. This kind of proof lowers risk and increases the likelihood of widespread adoption.

Market Potential: Autoimmune diseases are a large and growing market. If the technology has the potential to address multiple autoimmune conditions (e.g., rheumatoid arthritis, lupus, MS), this significantly expands its value. Large pharma companies often evaluate the size of the patient population, treatment costs, and long-term revenue potential.

Competitive Landscape: If the market is currently underserved or there's little competition for a comprehensive solution, the acquisition price could be much higher. However, if there are other companies developing similar technologies, the price might be more competitive or lower.

Regulatory Approvals: The stage of regulatory approvals would also affect the price. If the technology is already approved or close to approval, the acquisition price will be higher, as the acquirer can bring the product to market faster.

Intellectual Property Portfolio: Having patents, proprietary technology, and exclusive licenses would add considerable value to the acquisition price, as it would offer a competitive edge.

Strategic Fit and Synergies: Large pharma companies often acquire for strategic reasons, such as expanding their pipeline or gaining access to a new market. If the target company's product could complement or enhance the acquiring company's existing portfolio, that could drive up the price.

In terms of actual numbers, acquisitions in this space can range from hundreds of millions to several billion dollars, depending on these factors. For instance, the acquisition of companies with groundbreaking medical technology has seen values anywhere from $1 billion to over $10 billion. For example, Gilead's $11.9 billion acquisition of Kite Pharma in 2017 was driven by the potential of its CAR-T cell therapy, which was a highly innovative treatment at the time.

Ultimately, if your hypothetical company had a world-first diagnostic and treatment for autoimmune diseases, it would likely be worth several billion dollars at the very least, with a premium depending on its success in clinical trials, market potential, and regulatory approvals.

* for = form

Would have been good if they released a summary of the main bullet points discussed in the interview as an RNS (for wider exposure) as a for of operational update

...and another one...4.50 down to 3.65 momentarily

The MM's seem desperate for these shares....lots of momentary big drops occurring to hit those stop losses to scoop up some shares

WHY HAS IMMUPHARMA BEEN INVITED TO JP Morgan Conference and Biotech Showcase 2025

ChatGPT said:

ChatGPT

ImmuPharma has likely been invited to present at major industry events like the JP Morgan Healthcare Conference and the Biotech Showcase 2025 because of significant progress in their drug development pipeline, especially the breakthrough announced for Lupuzor in treating systemic lupus erythematosus (SLE). Being invited to such prestigious events is often an indication of several factors that make a company attractive to investors, analysts, and industry leaders:

1. Clinical Milestones and Breakthroughs:

Lupuzor's Phase 3 Success: The recent announcement of Lupuzor's Phase 3 clinical trial success is a key factor. Positive clinical trial results for a drug that targets a serious condition like lupus are highly valued in the biotech and pharmaceutical sectors. Successful trials demonstrate the potential for regulatory approval and commercialization, making ImmuPharma an interesting company to watch.

These breakthroughs attract attention from both potential investors and pharmaceutical partners, and events like the JP Morgan Conference and Biotech Showcase serve as platforms for companies to showcase their advancements.

2. Investment and Partnership Opportunities:

Both the JP Morgan Healthcare Conference and the Biotech Showcase are pivotal events for biotech and pharmaceutical companies to meet with potential investors, financial analysts, and industry leaders. By being invited, ImmuPharma is given a high-profile platform to engage with venture capitalists, pharma companies, and other stakeholders.

Strategic partnerships are often forged at these events, and ImmuPharma may be seeking to secure additional funding or partner with larger pharmaceutical companies to advance Lupuzor and other pipeline candidates.

3. Company Visibility and Recognition:

Being invited to these events signifies a recognition of ImmuPharma's potential within the biotech industry. High-profile events like these highlight promising biotech companies, especially those with innovative therapies in late-stage clinical trials, such as Lupuzor for lupus.

These events allow ImmuPharma to increase its visibility within the industry, attract new investors, and raise awareness about its therapeutic candidates.

4. Strong Investor and Analyst Interest:

As ImmuPharma continues to demonstrate positive results, there is likely increased investor interest in the company. This can lead to invitations to these events where potential investors and analysts want to learn more about the company’s future prospects, business strategy, and financial health.

The JP Morgan Healthcare Conference is particularly significant for the biotech sector, and being part of it suggests that ImmuPharma is seen as a company with promising growth potential.

5. Positioning for Future Capital Raises:

ImmuPharma may also be preparing for potential fundraising rounds or seeking to attract addi